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Pathogenic fungi have become increasingly important due to a wide range of
fungal infections worldwide and emergence of drug resistant strains. Cryptococcus
neoformans is an opportunistic fungal pathogen that causes mostly pulmonary infections,
meningitis and meningoencephalitis. The rate of mortality in males is higher compared to
females. Testosterone, the major steroid hormone in males, has been shown to affect the
C. neoformans pathogenicity. Searching for an effective antifungal drug against C.
neoformans, in particular for males, is a matter of importance. Scytovirin is a lectin with
newly discovered antifungal activity associated with cell wall interaction. Scytovirin was
tested against two pathogenic strains of C. neoformans, 24067 and H99S, in the presence
of testosterone to determine its effects on major virulence factors (polysaccharide capsule
and melanization) and budding. The results showed Scytovirin not only reduced capsule
size in strain H99S in the presence of testosterone, but also induced melanization and
altered the time course of budding for strain 24067. Thus, Scytovirin, with inhibitory
effects on C. neoformans, is a new and potential antifungal agent with potential increased
potency in the higher mortality male population.

iv

ACKNOWLEDGMENTS

It would be laborious work to go around such an aspect without the assistance and
support of a number of experts. At the first glance it would be my pleasure to convey my
especial thanks to Dr. Robert McFeeters for positioning me as a member of the best lab
group at the University of Alabama in Huntsville and putting me on a right track in doing
my project. It is unconceivable to get around this work without constant assistance and
encouragement he furnished. I will always remember the great opportunities he created
for me and tolerance he put up with. I also admit my special thanks to my committee
members Dr. Debra Moriarity and Dr. Luis Cruz-Vera for their invaluable insight,
recommendations and encouragement all the way through. I wish you all my best. I
admit my great thanks to the biology department for assisting my graduate education. I
would appreciate my family and friends for their steady pursuant and support. In the
absence of them I would not be able to accomplish such a difficult rout.

vi

TABLE OF CONTENTS
Page
LIST OF TABLES………………………………………………………………………..ix
LIST OF FIGURES…………………………………………………………………….....x
CHAPTER ONE: INTRODUCTION ................................................................................. 1
1.1 Antifungals ................................................................................................................1
1.2 Pathogenic Fungi……………………………………………………………………2
1.3 Cryptococcus……………………………………………………………………….2
1.4 Gender Based Infection of C. neoformans…………………………………………5
1.5 Capsule of C. neoformans………………………………………………………….5
1.6 Melanization of C. neoformans…………………………………………………...10
1.7 Scytovirin………………………………………………………………………....10
1.8 Effect of Scytovirin and Testosterone on C. neoformans………………………...12
CHAPTER TWO: MATERIALS AND METHODS……………………………………13
2.1 Growth of C. neoformans Strains 24067 and H99S……………………………....13
2.2 Broth Macrodilution Assay……………………………………………………….15
2.3 Capsule Induction of the Cryptococcus 24067 and H99S……………………......15
2.4 Cryptococcal Cell Staining for Microscopic View…………………………….....16
2.5 Capsule Size Measurement………………………………………………………..16
2.6 Preparation of Testosterone Solution……………………………………………..17
2.7 Effect of Scytovirin and Testosterone on the Cryptococcal Capsule……………..18

vii

CHAPTER THREE: RESULTS…………………………………………………………20
3.1 Broth Macrodilution MIC………………………………………………………...21
3.2 Induction of C. neoformans Capsule………………………………………………22
3.3 Effect of Scytovirin and Testosterone on the Cryptococcal Capsule……………..24
3.3.1 Effect of Scytovirin and Testosterone on the Capsule of strain 24067……. 24
3.3.2 Effect of Scytovirin and Testosterone on the Capsule of Strain H99S……. 26
3.4 Effect of Scytovirin on Cell Distribution Based on Budding Stages……………. 28
3.5 Effect of Scytovirin on Melanization of C. neoformans………………………… 36
CHAPTER FOUR: DISCUSSION……………………………………………….…….. 38
4.1 Inhibitory Effect of Scytovirin and Testosterone on Cryptococcal Cells……….. 38
4.2 Effect of Scytovirin on Melanization of Cryptococcal Cells……………………. 40
4.3 Effect of Scytovirin on Cryptococcal Budding Stages…………………………...42
CHAPTER FIVE: CONCLUSION…………………………………………………….. 43
REFERENCES…………………………………………………………………………. 47

viii

LIST OF TABLES
Table

Page

Table 1. YPD Broth (YEPD Broth) ................................................................................. 14
Table 2. YPD Agar ........................................................................................................... 14
Table 3. 100% Sabouraud Dextrose Broth ....................................................................... 14
Table 4. 10% Sabouraud Dextrose Broth ......................................................................... 16
Table 5. Scytovirin MICs against 24067 and H99S in two types of media. .................... 21

ix

LIST OF FIGURES
Figure

Page

Figure 1. Annual incidence of cryptococcal meningities worldwide in patients with low
CD4 count in 2014 (Adapted from Rajasingham et al., 2017) ……………………………..4
Figure 2. Synthesis of polysaccharide capsule in C. neoformans. The polysaccharide
capsule (C) is synthesized within the cell in Golgi apparatus (G), packed in multivesicular
body (MVB) inside the cell, transported across the cell wall (CW) via exocytosis and
physically attached to the cell wall (Adapted from Zaragoza et al., 2009) ……………....7
Figure 3. Repeating structure of GXM as a major component of polysaccharide capsule
in Cryptococcus neoformans (Adapted from Jones, 2017) ……………………………....8
Figure 4. Demonstration of polysaccharide capsule, three major components of the cell
wall (Mannan, β Glucan and Chitin) and membrane in C. neoformans (Adapted from
Jones, 2017) ……………………………………………………………………………....8
Figure 5. Two nearly identical domains of Scytovirin, red represents SD1and blue
represents SD2. Disulfide bonds are shown in yellow. Gray boxes show different residues
between SD1 and SD2 …………………………………………………………………. 11
Figure 6. Un-Induced and Induced C. neoformans. ........................................................ 22
Figure 7. Capsule size as a function of time for strain 24067. Error bars represent
standard error of the mean from 3 measurements………………………………………..23
Figure 8. Capsule size as a function of time for strains H99S. Error bars represent
standard error of the mean……………………………………………………………….23
Figure 9. Capsule diameter of C. neoformans 24067 as a function of time with various
concentrations of Scytovirin (Sc2). Scytovirin was added to the cells at 24*. Error bars
represent standard error of the mean ................................................................................. 25
Figure 10. Capsule diameter of C. neoformans 24067 as a function of time with
testosterone 10 nM. Testosterone 10 nM was added to the cells at 24*. Error bars
represent standard error of the mean.. ............................................................................... 25
Figure 11. Capsule diameter of C. neoformans 24067 as a function of time with various
concentrations of Scytovirin (Sc2) along with testosterone (T) 10 nM. Scytovirin and
testosterone were added to the cells at 24*. Error bars represent standard error of the
mean. ................................................................................................................................. 26

x

Figure 12. Capsule diameter of C. neoformans H99S as a function of time with various
concentrations of Scytovirin (Sc2). Scytovirin was added to the cells at 24*. Error bars
represent standard error of the mean. ................................................................................ 27
Figure 13. Capsule diameter of C. neoformans H99S as a function of time with
testosterone 10 nM. Testosterone 10 nM was added to the cells at 24*. Error bars
represent standard error of the mean. ................................................................................ 27
Figure 14. Capsule diameter of C. neoformans H99S as a function of time with various
concentrations of Scytovirin (Sc2) along with testosterone (T) 10 nM. Scytovirin and
testosterone were added to the cells at 24*. Error bars represent standard error of the
mean. ................................................................................................................................. 28
Figure 15. Budding stages of C. neoformans. .................................................................. 29
Figure 16. Budding stages of C.neoformans 24067 with 1.2 μM Scytovirin (Sc2)
compared to control at 24 hours........................................................................................ 30
Figure 17. Budding stages of C. neoformans 24067 with 1.2 μM Scytovirin (Sc2)
compared to control at 48 hours........................................................................................ 31
Figure 18. Budding stages of C.neoformans 24067 with 1.2 μM Scytovirin (Sc2)
compared to control at 72 hours........................................................................................ 32
Figure 19. Budding stages of C. neoformans H99S with 10 μM Scytovirin (Sc2)
compared to control at 24 hours........................................................................................ 33
Figure 20. Budding stages of C. neoformans H99S with 10 μM Scytovirin (Sc2)
compared to control at 48 hours........................................................................................ 34
Figure 21. Budding stages of C. neoformans H99S with 10 μM Scytovirin (Sc2)
compared to control at 72 hours........................................................................................ 35
Figure 22. Morphological feature of melanized and non-melanized cells of strains 24067
and H99S…………………………………………………………………………………36
Figure 23. Melanization of C. neoformans strain 24067 with various concentrations of
Scytovirin………………………………………………………………………………...37
Figure 24. Melanization of C. neoformans strain H99S with various concentrations of
Scytovirin………………………………………………………………………………...37

xi

CHAPTER ONE

INTRODUCTION

1.1 Antifungals
Recently, the importance of fungal infections has become noteworthy in the field
of medicine because of the wide range of population susceptible to infection. Patients
under treatment with immunosuppressed drugs, individuals with organ transplants and
those with AIDS are the most common populations at risk for fungal infections (Frosco
M, 1998). These populations have grown due, in part, to medical advances. Thus fungal
infections are a growing burden for worldwide healthcare.
Polyenes, pyrimidine analogs, echinocandins, and azoles are four major classes
of antifungals that have frequently been used for treatment of fungal infections over the
past few decades. Consequently, the emergence of antifungal resistance has increased
and antifungals therapies have become less effective (Sanglard, 2016). Also, each class
of antifungal has shown toxic side effects. For instance, amphotericin B, considered the
“gold standard,” is widely used against various pathogenic fungi but brings about
nephrotoxicity (Dixon & Walsh, 1996). Triazoles such as fluconazole and itraconazole
are more commonly used than amphotericin B due to their lower side effects.
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However, their spectrum of activity is limited to use in combination with other antifungal
drugs (Dixon & Walsh, 1996). Therefore, the increase in antifungal resistance coupled
with the limitation in activity of existing antifungal drugs makes the need for new
effective antifungals pressing.

1.2 Pathogenic Fungi
Currently fungal pathogenesis is considered one of the most serious health
problems worldwide. The frequency of fungal disease is highly elevated in
immunocompromised versus immunocompetent patients, with outcomes depending on
the fungal species. Overall fungi require four characteristics to infect humans: high
temperature tolerance, ability to invade the human host, lysis and absorption of human
tissue, and resistance to the human immune system (Kohler, Casadevall, & Perfect,
2015). The spectrum of human fungal pathogens encompasses numerous diseases with
afflictions extending from the outer surface of the skin and mucosal surfaces to infection
of internal organs. Fungal infections kill one and a half million people worldwide every
year (Kim, 2016; Reedy, Bastidas, & Heitman, 2007).

1.3 Cryptococcus
One of the major fungal pathogens is Cryptococcus neoformans. In terms of
epidemiology, Cryptococcus neoformans is found globally with prevalence among
untreated patients with AIDS (Antinori, 2013). It contains four distinct serotypes, A, B,
C and D which are identified by two C. neoformans varieties (var). Serotypes A and D
belong to C. neoformans var. neoformans and serotypes B and C belong to C.
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neoformans var. gattii (Dromer, Gueho, Ronin, & Dupont, 1993), now considered a
separate strain referred to as C. gattii. Serotype A is most prevalent in North and South
America while serotype D, making up only 9% of reported cases, is predominantly found
in Europe (Banerjee, Datta, & Casadevall, 2004). C. gattii has the highest prevalence
(35-100% of reported cases) in Australia, Mexico, many South American countries,
Hawaii, southern California, and many Asian countries to the north of the Equator
(Cambodia, Thailand, Vietnam, Nepal), as well as in central Africa. Serotype B was
about five times more common than serotype C (Banerjee et al., 2004). Being a global
threat with increasing incidence, new and potent antifungals are needed for effective
treatment of cryptococcal infections.
Among the various fungal infections, cryptococcosis has become increasingly
important (Kwon-chung et al., 2014). Cryptococcosis is caused by the two etiological
agents, Cryptococcus neoformans and Cryptococcus gattii, although both C. neoformans
and C. gattii belong to the phylum Basidiomycota, each has its own ecological niche and
prevalence of infection. Pigeon guano and higher plants are two common habitats
occupied by C. neoformans and C. gattii, respectively. Lungs and the central nervous
system are two main affected sites of cryptococcosis, and infection with C. neoformans
widely occurs in immunocompromised patients. Conversely C. gattii mostly targets
immunocompetent patients with significantly lower occurrence in immunocompromised
individuals (Gibson & Johnston, 2015; Nielsen, Obaldia, & Heitman, 2007).
Cryptococcal infections take place through breathing in spores and dehydrated
yeast cells (Buchanan & Murphy, 1998; Chun & Madhani, 2010). Once inhaled and
settled in the lung tissue, the infection proceeds to initiation of pulmonary infection or
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spread over influencing other organs and finally invasion of the central nervous system
(Guerra, Seabra, Souza, & Rozental, 2014). This pathogenic yeast causes an estimated 1
million cases of pulmonary and cryptococcal meningitis including more than 600,000
deaths every year (Janbon et al., 2014). 30% of AIDS patients in sub-Saharan Africa
suffer from cryptococcal meningitis, which can be a cause of death among those without
access to antiretroviral therapy (Archibald et al., 2004). Figure 1 shows global burden of
cryptococcal meningitis in patients with low CD4 count in different parts of the world.

Figure 1 Annual incidence of cryptococcal meningities worldwide in patients with low
CD4 count in 2014 (Adapted from Rajasingham et al., 2017).
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1.4 Gender Based Infection of C. neoformans
C. neoformans epidemiology shows a large number of differences in infections in
male versus female patients. Most notably, there is a higher incidence of C. neoformans
infection in males than females (McClelland et al., 2013). Evidence about the population
of cryptococcal infected male and female populations before the prevalence of HIV
worldwide showed that susceptibility to C. neoformans is higher in males compared to
females. Also, the C. neoformans infected population during the HIV epidemic still
showed an increased rate of mortality in males than females. In terms of gender based
differences in infection, it has been found that estrogen and testosterone have different
effects on C. neoformans and reactivity of C. neoformans with testosterone results in a
decreased immune response (Guess, Rosen, & McClelland, 2018). Therefore it can be
concluded that C. neoformans infection is hormone related. Increased mortality in males
compared to females occurs and common antifungal agents are without increased
efficacy on infected males. Therefore searching for new antifungal agents, in particular
one that can effectively decrease the severity of infection in male patients, is a matter of
importance.

1.5 Capsule of C. neoformans
C. neoformans is exclusive among fungal pathogens since it is encapsulated by a
polysaccharide capsule (Kim, 2016). Pathogenicity of C. neoformans depends upon
several virulence factors (Li, Rautengarten, Heazlewood, & Doering, 2018; Pontes &
Frases, 2015). The polysaccharide (PS) capsule was found to be the major virulence
factor of C. neoformans. Studies demonstrated that the acapsular mutants fail to infect
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the host or they only slightly induce virulence (Buchanan & Murphy, 1998; Pontes &
Frases, 2015; Rocha et al., 2015). The PS capsule is physically attached to the cell wall
and is a barrier for macrophages to carry out phagocytosis (S. Frases et al., 2009; Li et al.,
2018; Vecchiarelli et al., 2013). During infection, capsular PS is released to the
extracellular space increasing the effective size of the cryptococcal cell. Getting larger
reduces the ability of the host immune system phagocyte to destroy or inactivate the
capsular cryptococci effectively (Li et al., 2018; Zaragoza, Telzak, Bryan, Dadachova, &
Casadevall, 2006).
The cryptococcal capsule is comprised mainly of two polysaccharides,
glucuronoxylomannan (GXM) and galactoxylomannan (GalXM) (Doering, 2009). It also
contains mannoproteins as a minor component (Zaragoza et al., 2009). The hypothesized
secretory pathway of capsular PS suggests that it is synthesized inside the cell and
transported to the cell wall by vesicles through exocytosis (Doering, 2009; Rodrigues,
Nimrichter, Oliveira, Nosanchuk, & Casadevall, 2008; Yoneda & Doering, 2006) (Figure
2).
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Figure 2 Synthesis of polysaccharide capsule in C. neoformans. The polysaccharide
capsule (C) is synthesized within the cell in Golgi apparatus (G), packed in multivesicular
body (MVB) inside the cell, transported across the cell wall (CW) via exocytosis and
physically attached to the cell wall (Adapted from Zaragoza et al., 2009).

Capsule morphology is the result of the arrangement of these three molecules so
that they make a filamentous network (Araújo et al., 2016) with size ranges from 0.5-1.0
μm from the cell wall to 10-80 μm, depending on their existing condition (McFadden &
Casadevall, 2001). The plentiful capsule component, GXM, is a linear mannose (Man)
polymer including single glucuronic acid and xylose side chains (Li et al., 2018) (Figure
3). Pathogenicity of C. neoformans mostly depends upon GXM as it contains ~90% of
the capsular PS structure (Yoneda & Doering, 2006). The second polysaccharide,
GalXM, is comprised of a galactose structure with single galactofuranose (GaLf) and
galactomannan side chains making a different number of glucuronic acid and xylose
residues (Li et al., 2018).
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Figure 3 Repeating structure of GXM as a major component of polysaccharide capsule
in Cryptococcus neoformans (Adapted from Jones, 2017).

Assembly of capsular PS on the cell surface requires connection of the capsular
components to the cell wall (Susana Frases, Nimrichter, Viana, Nakouzi, & Casadevall,
2008). Carbohydrate structures of the cell wall containing glucan and chitin, together
with the complex polysaccharide capsule, enables pathogens to withstand host defenses
and bring about disease (Li et al., 2018; Yoneda & Doering, 2006) (Figure 4).

Figure 4 Demonstration of polysaccharide capsule, three major components of the cell
wall (Mannan, β Glucan and Chitin) and membrane in C. neoformans (Adapted from
Jones, 2017).
8

Cryptococcal cell wall contains α- and β-glucans (Mukaremera et al., 2018).
Among glucan compositions, polysaccharide α-1,3-glucan is one of the essential factors
for connection of the capsule to the cell wall (Fonseca et al., 2009; Reese & Doering,
2003). Inhibition of α-1,3-glucan expression or removing it by α-1,3-glucanase can
remodel the cell wall in a way that the capsule fails to connect to the cell wall
appropriately, making the cryptococci cell avirulent or less virulent (Reese & Doering,
2003; Reese et al., 2007). In fungal cells N-acetylglucosamine (GlcNAc) is a monomeric
unit of chitin and plays an important structural role on the cell surface. In the course of
infection with C. neoformans, synthesis of GlcNAc-containing molecules and capsular
polysaccharides increases in parallel and it has been found that GXM, the major capsular
component, has affinity for the molecules containing GlcNAc (Fonseca et al., 2009).
Deacetylation of chitin results in the formation of chitosan which is a linear
polysaccharide with different proportions of D-glucosamine and N-acetyl-D-glucosamine
in its structure (Zakaria, Zakaria, Musa, Hamilin, & Zulkifly, 2012). Chitosan is one of
the other important molecules in the cryptococcal cell wall. Cells lacking chitin and its
deacetylated derivatives show impaired cell wall-capsule connection and changes in the
regular formation of capsule on the cell surface (Baker, Specht, Donlin, & Lodge, 2007;
Fonseca et al., 2009). Pathogenicity of C. neoformans can be increased by its capsule
enlargement under stress conditions such as period of in vivo infection or growth in the
existence of low iron, mammalian serum, and physiological concentration of carbon
dioxide in vitro (Movahed et al., 2015).
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1.6 Melanization of C. neoformans
Another virulence factor that contributes to the pathogenicity of C. neoformans is
melanin formation. C. neoformans produces melanin to protect itself against stress
conditions and immune responses such as oxidative stress and invasion of macrophages
(Mednick, Nosanchuk, & Casadevall, 2005; Pereira, Bueno, Dias, Paula, & Siqueira,
2009). Formation of melanin tightly depends on the expression of laccase enzyme and
the presence of melanin precursors (Waterman et al., 2007). Data from immuno-electron
microscopy has shown that laccase is localized to the carbohydrate cell wall. Therefore,
peripheral localization of laccase on the C. neoformans cell wall allows this enzyme to
activate melanin production through oxidation of various phenolic compounds (Zhu &
Williamson, 2004). Once melanin is formed it is deposited in the cell wall (Eisenman,
Frases, Nicola, Rodrigues, & Casadevall, 2009). Melanization of C. neoformans is of
particular interest to this research because it can be investigated as one of C. neoformans
defense mechanisms against antifungals.

1.7 Scytovirin
Scytovirin is considered to be a strong antiviral lectin which is found in the
Cyanobacterium called Scytonema varium. It has been produced as a recombinant
protein in E. coli (Moulaei et al., 2007). Scytovirin has significant inhibitory activity
against human immunodeficiency virus (HIV) (Garrison et al., 2014; Moulaei et al.,
2007). Thus Scytovirin has the potential to become a pharmaceutical agent for
prevention of this viral infection (Moulaei et al., 2007). The molecular weight of
Scytovirin is 9.7 KDa (Xiong, O’Keefe, Botos, Wlodawer, & Mcmahon, 2006) and it is a
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single polypeptide chain of 95 amino acids, with a conserved internal 39 amino acid
repeat (McFeeters et al., 2013; Moulaei et al., 2007). Structural analysis of Scytovirin
has shown two domains for this protein, SD1 (residue 1-48) and SD2 (residue 49-95).
Scytovirin contains one inter-domain disulfide bond which is formed by Cys7 of SD1 and
Cys55 of SD2 (Moulaei et al., 2010). It has been reported that Scytovirin does not have
regular secondary structure (Moulaei et al., 2007) (Figure 5).

Figure 5 Two nearly identical domains of Scytovirin, red represents SD1and blue
represents SD2. Disulfide bonds are shown in yellow. Gray boxes show different residues
between SD1 and SD2.

It has been found that Scytovirin has antifungal activity against different
serotypes of C. neoformans and exerts its inhibitory effect through the cell wall (Jones,
Mcclelland, Mcfeeters, & Mcfeeters, 2017). Biochemical analysis of C. neoformans cell
wall shows chitin, glycoproteins and glucans as the main components (Muszewska,
Pilsyk, Perlinska-Lenart, & Kruszewska, 2018). Although C. neoformans contains a
large amount of mannose in its polysaccharide capsule, Scytovirin binds high mannose
oligomers of N-linked fungal glycans very specifically (W.Adams et al., 2004). The
localization of Scytovirin on the cryptococci cell wall was shown by fluorescence
confocal microscopy (Jones et al., 2017). Binding properties of Scytovirin to C.
11

neoformans and its antiviral activity creates an insight into its antifungal properties. It
has been found that Scytovirin has antifungal activity against pathogenic fungi C.
neoformans and C. gattii with different degrees of inhibition for each cryptococcus
variety so that serotype D from C. neoformans and serotypes B and C from C. gattii are
more inhibited by Scytovirin. Additionally, combination of Scytovirin and other
antifungals such as amphotericin B, flucytosine and fluconazole revealed synergy (Jones
et al., 2017). Thus further investigation of the antifungal properties of Scytovirin is
warranted.

1.8 Effect of Scytovirin and Testosterone on C. neoformans
Scytovirin, a novel antifungal lectin, was used in this study to determine whether
it has significant impact on C. neoformans cells in the presence of testosterone. Because
the occurrence of C. neoformans infections caused by serotypes A and D is more frequent
worldwide than other serotypes, this study has focused on the strains 24067 and H99s
which belongs to serotypes D and A, respectively.
Since the polysaccharide capsule is the most important virulence factor for C.
neoformans pathogenicity, this study focused on the effect of Scytovirin and testosterone
on capsule size of the cells. Also melanization was investigated visually based on
morphological features of the cell wall in cells exposed to Scytovirin. Lastly, the
budding stages of cells were classified based on their morphological shape to determine
the effect of Scytovirin on the budding process.
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CHAPTER TWO

MATERIALS AND METHODS

2.1 Growth of C. neoformans Strains 24067 and H99S
In this study, cells are used initially from frozen stock and grown in yeast extract
peptone dextrose (YEPD or YPD) broth media. To prepare broth culture, 10 μl of 24067
or 50 μl of H99S frozen stock were added to 3 mL of YPD broth media and incubated at
37 °C in a rotary shaker with moderate shaking of 150 rpm for 3-4 days. These cultures
were streaked on the YPD agar plates and incubated at 37 °C for 4 days until colonies
with creamy and butyrous (buttery) appearance show up on the plate. Cells from a
colony on the YPD plate were checked for their capsule size by staining the cells with
India ink and visualizing them using 100x magnification power of the light microscope.
A single colony from the YPD plate was used to inoculate 5 mL of 100% Sabouraud
dextrose medium which was then incubated at 37 °C in rotary shaker at 150 rpm for
~18h. The culture was grown to an OD600 of ~0.67 (mid-log phase), equivalent to the
concentration of ~ 2 x 107 cells/mL. The media used in this section was made based on
the following recopies:
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Table 1 YPD Broth (YEPD Broth).
Ingredients

Grams / Liter

Peptic digest of animal tissue

20

Yeast extract

10

Dextrose

20

Final PH (at 25 °C)

6.5±0.2

Table 2 YPD Agar.
Ingredients

Grams / Liter

Peptone

20

Yeast extract

10

Glucose

20

Agar

20

Table 3 100% Sabouraud Dextrose Broth.
Ingredients

Grams / Liter

Enzymatic Digest of Casein

5

Enzymatic Digest of Animal Tissue

5

Dextrose

20

Final PH (at 25 °C)

5.6±0.2
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2.2 Broth Macrodilution Assay
Broth macrodilution was performed in two different media, RPMI/MOPS and
10% Sabouraud dextrose broth to determine whether there is a change in minimum
inhibitory concentration (MIC) of Scytovirin using different media. For broth
macrodilution MIC testing, Scytovirin with initial concentration of 400 μM was serially
diluted by half in PBS and added to 5 mL snap cap tubes in 100 μl aliquots. 100%
Sabouraud dextrose broth culture was diluted 1:100 for cell count using Bright-Line™
hemocytometer. Cells were then diluted to a concentration of 2.22 x 103 cells/mL in the
media. Aliquots of 900 μl of 2.22 x 103 cells/mL in the media was added to the tubes
containing Scytovirin for total volume of 1 mL and final cell concentration of 2000
cells/mL. Final concentrations of Scytovirin in each culture were 0, 0.1, 0.3, 0.6, 1.3, 2.5,
5.0, 10, 20 and 40 μM. The cultures were incubated at 37 °C in rotary shaker with
moderate shaking of 150 rpm for 72 hours. The culture without Scytovirin and a culture
containing 1 μM final concentration of amphotericin B were used as the positive and
negative controls, respectively.

2.3 Capsule Induction of the Cryptococcus 24067 and H99S
Capsule growth can be induced by several factors including low nutrient
conditions, serum and CO2 exposure. In this experiment, the low nutrient condition was
used for capsule induction. A single colony of C. neoformans on the YPD agar plate was
used to inoculate 100% liquid Sabouraud dextrose medium which was then incubated at
37 °C in rotary shaker at 150 rpm. Once the culture reached an OD600 of ~ 0.67, it was
diluted 1:100 in 10% Sabouraud dextrose broth medium buffered to pH 7.3 with 50 mM
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MOPS, incubated at 37 °C in rotary shaker with moderate shaking of 150 rpm to induce
the capsule.

Table 4 10% Sabouraud Dextrose Broth.
Ingredients

500 mL

50 mM MOPS

4.69 grams

100% Sabouraud Dextrose Broth

50 mL

Final PH (at 25 °C)

7.3

2.4 Cryptococcal Cell Staining for Microscopic View
The 10% Sabouraud dextrose broth cell cultures were pelleted at 870 g for 5
minutes. The supernatant was discarded and the pellet was washed 3 times. Each time
the supernatant was discarded, the pellet was resuspended in the same volume of PBS
before re-pelleting the culture. After the last wash, 5-10 μl of the supernatant was kept at
the bottom of the tube and the rest of it decanted and the pellet resuspended in the
remaining supernatant. 4 μl of suspension was dropped on the glass slide and mixed with
2 μl of 0.9% saline and 1.4 μl India ink. A coverslip was put on the mixture without foam
formation under it. The prepared sample was visualized with 100x magnification on a
light microscope.

2.5 Capsule Size Measurement
Because the prepared sample may contain cells with different capsule size at
budding stages, a field of view representative for all types of the cells was selected.
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At least 50 cells from the selected field of view were pictured using AmScope software
v3.7. The diameter of the capsular space in each cell was determined by measuring the
diameter of the spherical cell body without capsule and subtracting it from the diameter
of the spherical volume of the entire cell (including cell body and capsule around it)
(McFadden & Casadevall, 2001). The unit of measurement in AmScope software is a
pixel. Thus, in order to convert pixel to micron the calibration slide, containing 100
divisions of 0.01 mm, was visualized microscopically by 100x magnification power. 10
Divisions were measured in terms of pixels and the average of them was used to generate
the conversion of 446 pixels = 10 μm. Diameter were measured in pixels and then
converted to microns using the above equation.

2.6 Preparation of Testosterone Solution
A testosterone solution was made from its powder with the molecular formula of
C19H28O2 and molecular weight of 288.42 g/mol. Testosterone is soluble in both ethanol
and DMSO with maximum concentration of 25 mM and 100 mM, respectively
(www.tocris.com). Because DMSO has an inhibitory effect on growth of cryptococcal
cells, absolute ethanol was used as a solvent to make the testosterone solution in which 5
mg of testosterone powder was measured with analytical balance and added to 17.34 mL
ethanol to make 1 mM solution. The 1 mM solution was diluted 1:1,000 in 100% ethanol
to get the concentration of 1 μM. In order to fully dissolve the testosterone in ethanol, a
rapid stirring method was used.

17

2.7 Effect of Scytovirin and Testosterone on the Cryptococcal Capsule
To measure the effects on capsule, 10% Sabouraud dextrose broth cell culture was
tested with Scytovirin, the mixture of Scytovirin and testosterone, and testosterone itself
in parallel. The effect of testosterone on the Cryptococcal capsule, with or without
Scytovirin, was tested based on its physiological concentration of 10 nM (Kelsey et al.,
2014). The concentration of Scytovirin was determined based on the MIC value in 10%
Sabouraud dextrose broth medium. To investigate the range of changes in the
cryptococcal capsule size that may occur in the presence of high and low concentrations
of Scytovirin, twice, equal, half and one quarter of the MIC value were selected.
Scytovirin with an initial concentration of 13.3 μM was serially diluted by half in PBS
and added to 5 mL snap cap tubes in 90 μl aliquots. 10 μl ethanol was added to each tube
and the solution brought up to 100 μl. Final concentrations of Scytovirin in each tube
were 1.19, 0.6, 0.3 and 0.14 μM. To determine the effect of Scytovirin and testosterone
on the capsule size of the cells, 10 μl of 1 μM testosterone was added to each tube instead
of ethanol for final physiological concentration of 10 nM. For testing the effect of
testosterone with physiological concentration of 10 nM on the capsule size, 90 μl PBS
was mixed with 10 μl of 1 μM testosterone in a snap cap tube. Also, a control sample
was made by combining 10 μl ethanol (solvent for testosterone) and 90 μl PBS (solvent
for Scytovirin) in a tube. Lastly, in order to keep the cells in a stable capsule inducing
condition, 900 μl of 10% Sabouraud dextrose broth cell culture at OD600 of 0.22,
equivalent to the concentration of 6.2 x 106 cells/mL, was added to the all tubes for total
volume of 1 mL and a final concentration of 5.58 x 106 cells/mL. All of the cultures were
incubated at 37 °C in rotary shaker with moderate shaking of 150 rpm.
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The same experimental procedure was followed as explained above for strain
H99S with the exception of Scytovirin concentrations which were prepared based on the
MIC value for H99S. To make twice, equal, half and one quarter of the MIC value,
Scytovirin was serially diluted by half in PBS for final concentrations of 10, 5, 2.5 and
1.2 μM. Lastly, 900 μl of 10% Sabouraud dextrose broth cell culture at OD600 of 0.26,
equivalent to the concentration of 6.15 x 106 cells/mL, was added to the all tubes
explained above for total volume of 1 mL and final concentration of 5.53 x 106 cells/mL.
Cells from each sample were visualized at 24, 48 and 72 hours (for both 24067
and H99S strains). At each time point, 100 μl of each sample was transferred to an
Eppendorf tube, and cells were prepared for staining as described previously.
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CHAPTER THREE

RESULTS

The novel antifungal lectin, Scytovirin, was tested in combination with
testosterone to determine the effect on cryptococcal capsule size. This combination was
also tested to examine the effects on growth, distribution of the cells based on their
budding stages, and melanization. These together can determine how Scytovirin and
testosterone can effectively reduce the pathogenicity of Cryptococcus neoformans, which
is globally more frequent in males compared to females. For this purpose, a range of
Scytovirin concentrations were used to inhibit the growth of C. neoformans in relation to
the MIC determined from a macrodilution assay. Scytovirin was combined with a
physiological concentration of testosterone (10 nM) to determine any significant changes
in cryptococcal cells. The capsule size of the cells in each sample was compared to the
control containing cells in PBS and ethanol, the solvents for Scytovirin and testosterone,
respectively. Cells were categorized as normal, early budding, mid budding and late
budding cells based on the different budding stages in the cryptococcal cell cycle to
determine whether Scytovirin interferes with budding. The effect of different
concentrations of Scytovirin on melanization was investigated by following the
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increasing or decreasing trend of the percentage of cells with a thick cell wall versus
concentrations of Scytovirin.
Collectively, ten samples were tested for this experimental procedure in which
only 10 nM testosterone was used with various concentrations of Scytovirin for their
range of effect on the cryptococcal capsule size. Classification of the cells as normal,
early budding, mid budding, late budding, melanized and non-melanized was done
visually based on cell morphology. Two experimental strains of C. neoformans, 24067
(serotype D) and H99S (serotype A), were used for this experiment, treated identically to
compare their statistical results.

3.1 Broth Macrodilution MIC
MIC values of Scytovirin for broth macrodilution in two different media (Table
5), RPMI/MOPS and 10% Sabouraud dextrose broth, were found to be more effective at
a lower concentration in 10% Sabouraud dextrose broth for both cryptococcal strains.

Table 5 Scytovirin MICs against 24067 and H99S in two types of media.

Media

C. neoformans strain

MIC [μM]

24067

0.6

H99S

5

24067

2.5

H99S

>40

10% Sabouraud dextrose Broth

RPMI/MOPS
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3.2 Induction of C. neoformans Capsule
Cell capsules were induced and measured at 24-hour intervals up to 72 hours in
order to determine the appropriate time point to add Scytovirin and testosterone to the
cells. Morphological features of un-induced and induced cells are shown in Figure 6.
While measuring the capsule size of the cells, budding cells were separated from
individual cells to compare their capsule size under the stress conditions. The measured
result revealed that the mean of the capsule diameter was slightly higher in budding cells
in comparison to individual cells. Consequently, all cells were added together for final
measurement. In Figure 7 and 8, time 0 represents the capsule size of the cells
immediately after transition into the induction media. Capsule enlargement continued
and reached to its maximum size at 48 hour and was repressed while getting close to 72
hours.

Un-induced

Induced

Figure 6 Un-Induced and Induced C. neoformans.

22

24067

Mean Capsule Diameter (μm)

14
12
10
8
6
4
2
0
0

24

48

72

Time (hours)

Figure 7 Capsule size as a function of time for strain 24067. Error bars represent
standard error of the mean from 3 measurements.
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Figure 8 Capsule size as a function of time for strains H99S. Error bars represent
standard error of the mean.
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3.3 Effect of Scytovirin and Testosterone on the Cryptococcal Capsule
Based on the preliminary data, the 24 hour time point after capsule induction was
selected as the starting point to add Scytovirin and testosterone to the culture. This was
chosen because at 24 hours cells in the culture with OD600 of 0.16 and concentration of 6
x 106 cells/mL are in the middle of capsule enlargement and possible repression of
capsule growth by Scytovirin and testosterone prevents cells from reaching their
maximum capsule size. In this experiment, cells were tested with Scytovirin and
testosterone separately and together to determine if any change in capsule size is the
result of cells being exposed to only Scytovirin, testosterone or both. Each sample was
compared to the control containing cells in ethanol and PBS, the solvents for testosterone
and Scytovirin, respectively.

3.3.1 Effect of Scytovirin and Testosterone on the Capsule of Strain 24067
Strain 24067 was exposed to Scytovirin and testosterone and were imaged after
24, 48 and 72 hours to measure the effects on capsule size. The data showed that
Scytovirin and testosterone separately do not have an effect on capsule size when
compared to the control (Figures 9 and 10). Also, capsule size of the cells did not
significantly change in the presence of Scytovirin and testosterone together (Figure 11).
Thus it does not appear that Scytovirin and testosterone have any effect on the capsule
production in 24067 cells.
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Figure 9 Capsule diameter of C. neoformans 24067 as a function of time with various
concentrations of Scytovirin (Sc2). Scytovirin was added to the cells at 24*. Error bars
represent standard error of the mean.
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Figure 10 Capsule diameter of C. neoformans 24067 as a function of time with
testosterone 10 nM. Testosterone 10 nM was added to the cells at 24*. Error bars
represent standard error of the mean.
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Figure 11 Capsule diameter of C. neoformans 24067 as a function of time with various
concentrations of Scytovirin (Sc2) along with testosterone (T) 10 nM. Scytovirin and
testosterone were added to the cells at 24*. Error bars represent standard error of the
mean.

3.3.2 Effect of Scytovirin and Testosterone on the Capsule of Strain H99S
Strain H99S was exposed to Scytovirin and testosterone at OD600 of 0.26,
equivalent to the concentration of 6.15 x 106 cells/mL, and cells from each sample were
imaged after 24, 48 and 72 hours to measure the capsule size. The data revealed that
Scytovirin and testosterone separately do not have effect on capsule size when compared
to the control (Figures 12 and 13), whereas Scytovirin with 10 nM testosterone decreases
capsule size. The effect is most pronounced at 72 hours and at the highest concentration
of Scytovirin. At lower Scytovirin concentrations, no change in capsule size is observed
(Figure 14).
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Figure 12 Capsule diameter of C. neoformans H99S as a function of time with various
concentrations of Scytovirin (Sc2). Scytovirin was added to the cells at 24*. Error bars
represent standard error of the mean.
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Figure 13 Capsule diameter of C. neoformans H99S as a function of time with
testosterone 10 nM. Testosterone 10 nM was added to the cells at 24*. Error bars
represent standard error of the mean.
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Figure 14 Capsule diameter of C. neoformans H99S as a function of time with various
concentrations of Scytovirin (Sc2) along with testosterone (T) 10 nM. Scytovirin and
testosterone were added to the cells at 24*. Error bars represent standard error of the
mean.

3.4 Effect of Scytovirin on Cell Distribution Based on Budding Stages
Cells in each sample were classified as normal, early-budding, mid-budding and
late-budding cells based on their morphology to determine the effect of Scytovirin and
testosterone on duration of cell cycle phases (Figure 15). Different budding stages occur
at the different phases of the cell cycle. Normal, early-budding and late-budding cells are
grouped into interphase; however, referring each budding stage to its exact phase of cell
cycle is dependent on DNA content inside the cells (Yamaguchi, Ohkusu, Biswas, &
Kawamoto, 2007). Mid-budding cells can be grouped into mitotic phase or interphase
depending on the formation of mitotic spindles. In this study, the distribution of normal,
early-budding, mid-budding and late-budding cells in each sample was compared to the
control at time points of 24, 48 and 72 hours for strains 24067 and H99S. Results
revealed that the rate of early-budding and mid-budding cells increased at each time point
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by adding 1.2 μM Scytovirin to the 24067 cells (Figure 16-18), while the rate of budding
stages in strain H99S was changed slightly by adding 10 μM Scytovirin to the cells
(Figure 19-21).

Normal

Early-budding

Mid-budding

Figure 15 Budding stages of C. neoformans.
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Figure 16 Budding stages of C. neoformans 24067 with 1.2 μM Scytovirin (Sc2)
compared to control at 24 hours.
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Figure 17 Budding stages of C. neoformans 24067 with 1.2 μM Scytovirin (Sc2)
compared to control at 48 hours.
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Figure 18 Budding stages of C. neoformans 24067 with 1.2 μM Scytovirin (Sc2)
compared to control at 72 hours.
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Figure 19 Budding stages of C. neoformans H99S with 10 μM Scytovirin (Sc2)
compared to control at 24 hours.

33

48 h

80
Number of Cells (%)

70
60
50
40

ETOH+PBS:ctrl

30

Sc2 10 μM

20
10
0
Normal Cells

Early-budding

Mid-budding

Late-budding

Scytovirin 10 ϻM

Control

Figure 20 Budding stages of C. neoformans H99S with 10 μM Scytovirin (Sc2)
compared to control at 48 hours.
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Figure 21 Budding stages of C. neoformans H99S with 10 μM Scytovirin (Sc2)
compared to control at 72 hours.
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3.5 Effect of Scytovirin on Melanization of C. neoformans
Melanization is a defense mechanism in C. neoformans in which melanin is
collected in the cell wall making it thicker and chromatic. The population of melanized
cells in the samples containing Scytovirin was visually separated from non-melanized
cells so that cells with thick cell walls were considered as melanized cells (Figure 22).
The distribution of melanized cells with various concentrations of Scytovirin were
compared to each other and finally compared to control in order to determine the effect of
Scytovirin on melanin production.

The number of melanized cells in strain 24067

increased upon exposure to 1.2 μM Scytovirin and a declining trend was seen with
decreasing the concentration of Scytovirin to 0.6 μM and 0.3 μM at time points of 24, 48
and 72 hours (Figure 23). For strain H99S, the declining trend in melanization with
different concentrations of Scytovirin was only seen at the 24 hour time point (Figure
24).

Non-Melanized Cell

Melanized Cell

Figure 22 Morphological feature of melanized and non-melanized cells of strains 24067
and H99S.
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Figure 23 Melanization of C. neoformans strain 24067 with various concentrations of
Scytovirin.
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Figure 24 Melanization of C. neoformans strain H99S with various concentrations of
Scytovirin.

37

CHAPTER FOUR

DISCUSSION

4.1 Inhibitory Effect of Scytovirin and Testosterone on Cryptococcal Cells
The main purpose of this study was to determine the effect of Scytovirin and
testosterone on C. neoformans. It has been found that testosterone induces the release of
GXM from the capsule of C. neoformans in male patients with cryptococcal infection.
This can result in an increase of pathogenicity and depends on type of strain causing
infection (McClelland et al., 2013).
To determine whether the MIC value of Scytovirin against C. neoformans is
changed based on their growth condition, an MIC assay was performed in capsule
induction media, 10% Sabouraud dextrose broth, and the results were compared to
regular media, RPMI/MOPS. By determining MIC values of Scytovirin against these
strains, concentrations below and above the MIC value in 10% Sabouraud dextrose broth
media were selected and tested with and without testosterone for their efficacy on
cryptococcal capsule size. The broth macrodilution assay revealed a higher degree of
susceptibility to Scytovirin for strain 24067 than H99S in both regular and stressed
conditions, and it was found that Scytovirin is more effective in inhibiting both strains
with larger capsule size under stressed conditions.
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Although the polysaccharide capsule of strain 24067 is larger than H99S in
stressed conditions, Scytovirin inhibits strain 24067 more effectively than H99S
regardless of its capsule size.
It can be concluded from MIC values in stressed conditions and the localization of
Scytovirin to the cryptococcal cell wall (Jones et al., 2017) that Scytovirin does not
physically interfere with polysaccharide capsule, but instead affects the cell wall. Despite
Scytovirin showing antifungal properties against C. neoformans serotypes A and D, data
showed that capsule size of strains 24067 and H99S was not changed by exposure to
Scytovirin. Additionally, strain H99S but not 24067 showed susceptibility to the
combination of Scytovirin and testosterone in terms of decrease in capsule size.
Although Scytovirin by itself does not change the size of cryptococcal capsule, it is in
some degree effective in combination with testosterone to decrease capsule size in some,
but not all, cryptococcal strains. Also, testosterone showed close similarity to the control
in terms of not being effective in reducing capsule size of strains 24067 and H99S. So,
antifungal properties of Scytovirin against strain H99S can be improved by using
Scytovirin together with testosterone to increase the effect on capsule size of the cells.
Scytovirin, which is localized to the cryptococcal cell wall, showed a greater
effect on capsule size of strain H99S at high concentration in combination with
physiological concentration of testosterone. Although there is data available about the
structural properties of Scytovirin and its localization on C. neoformans, its mechanism
of action is a matter of consideration for future studies. The combined effect of
Scytovirin and testosterone on capsule size can be a result of their interaction to induce
changes in capsule size so that testosterone may have a significant impact on Scytovirin

39

or vice versa. The same experimental procedure was provided for both strains H99S and
24067, but their response to the external stimuli was not the same as each other. This
shows that C. neoformans serotypes A and D have distinguished intracellular and
extracellular properties. Noise in the trend lines of capsule size as a function of time
(Figures 9-14 in the Result section) can be investigated by repeating the experiment and
doing the cell count on a larger scale. For further research about significant level of
change in capsule size of strain H99S, concentrations of Scytovirin and testosterone
tested in this study can be increased in various proportions. The efficacy of Scytovirin
and testosterone together to reduce capsule size of strain H99S may be changed when
they are exposed to the cells in different induced conditions such as CO2 exposure,
mammalian serum, or low nutrient condition.

4.2 Effect of Scytovirin on Melanization of Cryptococcal Cells
In this study, melanization as a morphological change of cell wall was recognized
visually in population of cells exposed to Scytovirin, specifically at the highest
concentration used in this experiment. Cells with thicker and chromatic cell walls were
considered melanized cells. Melanization is another virulence factor of C. neoformans
and occurs when cryptococcal cells need to be protected from attack of immune effector
cells (Wang, Aisen, & Casadevall, 1995). Since Scytovirin acts as an antifungal
substance to inhibit cryptococcal cells, the cells produce melanin as a defense
mechanism. Although cells with a thicker, chromatic cell wall were visualized in both
strains 24067 and H99S, a greater population of melanized cells was found in strain
24067. This suggests that each of these strains reacts to stressed conditions differently.
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The expression of laccase enzyme is a key factor for melanization in cryptococcal cells. It
is directly affected by the amount of glucose available for cells. Low levels of glucose
result in more laccase enzyme localized to the cell wall (Waterman et al., 2007).
In this study, cells were placed in starvation conditions, 10% Sabouraud dextrose
broth, and incubated for 72 hours. An upward trend in melanization as a function of time
was observed in cultures with various concentrations of Scytovirin. This is consistent
with the fact that the expression of laccase enzyme increases in the presence of glucose
deprivation. In strain H99S melanization mainly occurred in cultures containing
Scytovirin 2.5 and 1.2 μM, while in strain 24067 an upward trend was seen in cultures
with Scytovirin 1.2, 0.6 and 0.1 μM. On the other hand, in strain 24067 melanization as a
function of Scytovirin concentration showed downward trend from 1.2 μM to 0.3 μM at
each time point. Strain H99S, in contrast, only shows downward trend from 10 μM to 1.2
μM at 24 hour. Data from strain 24067 indicates that Scytovirin initiates the response of
melanization during glucose deprivation. Also melanizaton is increased in strain 24067
which is more susceptible, so more stressed. These data suggest that strain, level of
glucose, and concentration of Scytovirin contribute to the outcome of C. neoformans
melanization. Since the data about melanization was established based on visualizing
cell wall appearance, further methods can be used to improve these findings. This
experiment can be performed with higher concentrations of Scytovirin, greater than 1.2
μM for strain 24067 and greater than 10 μM for strain H99S, and investigated for higher
populations of melanized cells compared to lower concentrations. Also, glucose rich
conditions can be replaced the starvation conditions in this experiment as a control for
cultures containing melanized and non-melanized cells. Transmission electron
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microscopy can be used for microscopic view of cell wall architecture of melanized cells
and non-melanized cells.

4.3 Effect of Scytovirin on Cryptococcal Budding Stages
In strain 24067 and H99S, cells containing the highest concentration of Scytovirin
were separated into different budding stages based on visual observation of budding
morphology to determine the effect of Scytovirin on budding state population. Strain
24067 showed consistent results of increased level of early-budding and mid-budding
cells at each time point, while no consistency was visualized in budding stages of strain
H99S in response to Scytovirin. Also, it was observed that, in strain H99S, the
population of normal cells was significantly higher than the rest of budding stages either
with or without Scytovirin at each time point. The data suggests that the mechanism of
action of Scytovirin may have a different effect on budding stages of strains 24067 and
H99S. Scytovirin can possibly arrest cryptococcal cells in early-budding and midbudding stages in strain 24067 and impair the cell cycle, while it has less or no effect on
the cell cycle of strain H99S. It has been found that the amount of DNA content in each
budding stage represents the appropriate phase of the cell cycle (Ohkusu, Hata, & Takeo,
2001; Yamaguchi et al., 2007). Finding the amount of DNA of each budding stage in this
study may give a new category for budding stages. This study can be improved by larger
scale of cells for classification and reclassifying budding stages based on DNA content
rather than morphological features.
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CHAPTER FIVE

CONCLUSION

Infection with Cryptococcus neoformans is considered one of the serious diseases
worldwide specifically among immunocompromised patients with HIV/AIDS.
Pathogenicity of C. neoformans depends on several virulence factors among which
polysaccharide capsule plays crucial role. One of the considerable points about
cryptococcal infection is that mortality rates differ in males compared to females so that
males are infected more frequently than females. Recently, testosterone and estrogen,
two major hormones in males and females, respectively, are found to affect cryptococcal
infection differentially. Therefore, cryptococcal infection is considered hormone related.
Although there are several antifungal drugs with different mechanisms to inhibit C.
neoformans and prevent cryptococcal infection, none of them have shown significant
effects on the male population compared to female population.
In this study, the novel antifungal lectin, Scytovirin, was tested together with
testosterone to detect the effect on C. neoformans capsule strains 24067 and H99S. The
findings showed that Scytovirin and testosterone do not change the capsule size of strain
24067; however, they change the capsule of H99S. Scytovirin inhibits the growth of C.
neoformans strains 24067 and H99S at their MIC values of 0.6 μM and 5 μM,
respectively.
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There is an effect on the capsule size of H99S, but not 24067 with exposure to
high concentration of Scytovirin in the presence of testosterone. Testosterone at the
physiological concentration of 10 nM does not inhibit the growth of either strain of C.
neoformans nor does it affect capsule size. Therefore, the impact of Scytovirin in the
presence of testosterone to decrease the capsule size of strain H99S makes it a better
antifungal agent in males compared to females.
For future research, Scytovirin and testosterone can be added to the cells at time
point 0, right after transferring the culture to 10% Sabouraud dextrose broth medium
when capsule of the cells are first induced. This test can determine whether Scytovirin
and testosterone can inhibit the initial capsule growth of the cells. The results of this test
can be compared to the preliminary data showed in result section, Figures 7 and 8, to
evaluate the effect of Scytovirin and testosterone on inhibition of capsule induction at 24,
48 and 72 hours. Furthermore, the capsule growth inhibition experiment can be
performed using CO2 exposure as a stressed condition to induce capsule of the cells. The
range of changes in capsule size can then be determined in the presence of Scytovirin and
testosterone.
Also, MIC assay can be performed with Testosterone itself and combined
Scytovirin and testosterone to determine their MIC value against C. neoformans, and
subsequently define whether testosterone can change the MIC value of Scytovirin. This
experiment is important because it helps to understand if significant effect of combined
Scytovirin and testosterone on Strain H99S in terms of diminishing its capsule size is due
to inhibitory effect of Scytovirin and testosterone or it directly affects the capsule size
without increasing inhibitory effect on the cells.
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Testosterone is a steroid hormone made from cholesterol and found in human and
animal cells. Ergosterol is a sterol, a subgroup of steroids. It is a compound mainly
found in the membrane of fungi. For this reason, it would be interesting to determine the
combined effect of ergosterol with Scytovirin on the capsule size of C. neoformans and to
compare the results to the effect of combined Scytovirin and testosterone. This
experiment may help to determine the affected sites by Scytovirin and testosterone in C.
neoformans, as well as to find other compounds that improve the effect of Scytovirin on
C. neoformans on reducing capsule size.
In this study, budding stages of strains 24067 and H99S was determined based on
the morphological feature of their buds. Based on our visual investigation through
budding stages of both strains it can be concluded that Scytovirin can impair the budding
process of strain 24067 by increasing the population of early-budding and mid-budding
cells, while no consistent change was seen in the budding process of strain H99S after
cells were exposed to Scytovirin. Cells arrested in early-budding and mid-budding stages
can take longer to double. Therefore for future study, CFUs (colony forming unit) can be
used to estimate the population of cells exposed to Scytovirin. To study the effect of
Scytovirin on the cell cycle of C. neoformans, each phase of the cell cycle can be
inhibited by an appropriate inhibitor. By inhibiting each phase, population of the
budding stages can be determined based on their morphological features and compared to
those exposed to Scytovirin. Performing this test with different strains of C. neoformans
can reveal the response of each strain to Scytovirin in terms of change in their cell cycle.
Melanization is a defense mechanism in C. neoformans strains 24067 and H99S.
Scytovirin triggers greater melanin production in strain 24067 than H99S under
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starvation conditions. The degree of melanization showed inverse correlation with the
nutrient level of growth environment so that as the level of glucose went down
melanization increased. Further experiments are needed to establish the role of
Scytovirin in this melanization process. For this purpose, an experiment can be
performed with higher concentrations of Scytovirin, greater than 1.2 μM for strain 24067
and greater than 10 μM for strain H99S, to compare the population of melanized cells to
that of lower concentrations of Scytovirin. Also, starvation conditions can be replaced by
glucose rich conditions in this experiment to characterize glucose effect on Scytovirin
induced melanization.
These future studies will continue to provide understanding into the antifungal
mechanism of Scytovirin and its affects in combination with testosterone. Greater
understanding of the mechanism and cellular impacts in different conditions furthers
antifungal development of this emerging new approach.
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